Navigation Links
Cell Therapeutics Retires 7.5% Convertible Senior Notes
Date:5/1/2011

SEATTLE, May 2, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) today announced that it has deposited $10.6 million in cash as trust funds with U.S. Bank National Association, as the trustee of the outstanding 7.5% convertible senior notes (the "Notes"), which is an amount sufficient to pay and discharge the entire amount due on the Notes, including accrued and unpaid interest.  

"Due to our successful efforts last year that resulted in a significant reduction of our debt, along with the retirement of the Notes, there now remains only one series of convertible senior notes on the balance sheet.  We plan to retire the remaining outstanding convertible senior notes at maturity in December 2011, which would leave CTI free of any remaining convertible debt," said James A. Bianco, M.D., CEO of CTI.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.celltherapeutics.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of CTI's securities. Specifically, the risks and uncertainties that could affect the development of CTI's products include risks associated with preclinical and clinical developments in the biopharmaceutical industry, including, without limitation, that CTI may experience unexpected delays in the regulatory approval process of its products, that CTI may not retire its remaining outstanding convertible senior notes at maturity in December 2011 and may not be free of any remaining convertible debt, CTI's ability to continue to raise capital as needed to fund its operations, competitive
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Talecris Biotherapeutics Announces First Quarter 2011 Results
2. Nektar Therapeutics Reports First Quarter 2011 Financial Results
3. Carmell Therapeutics Completes Series A Financing to Advance the Development of Novel Bioactive Plastics
4. Proteon Therapeutics Initiates Patient Enrollment in Phase 2 Clinical Study of PRT-201 in Hemodialysis Patients
5. Talecris Biotherapeutics to Report First Quarter 2011 Financial Results
6. Precision Therapeutics ChemoFx® Demonstrates Significant Role in Selection of Chemotherapy Doublets in Non Small Cell Lung Cancer
7. MabVax Therapeutics Receives $1.8 Million in a Phase 2 Small Business Innovation Research Program Award From the National Cancer Institute
8. Precision Therapeutics Announces New Tumor Profiling Product to Augment Utility of ChemoFx® and Further Personalize Cancer Treatment
9. Reportlinker Adds Antiviral Therapeutics - Technologies, Markets and Companies
10. Orexigen® Therapeutics Presents Additional Contrave® Data from Phase 3 COR-II Trial on 24-Hour Ambulatory Blood Pressure Monitoring
11. Orexigen® Therapeutics Announces Upcoming Data Presentation at the American College of Cardiology Annual Scientific Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... -- - Development of a Novel Taxane ... Platform - To be Presented on Tuesday, Apr 21, ... of Antibody-drug Conjugates Using an anti-HER2 Monoclonal Antibody and ... 19, 1:00 PM EST Invictus Oncology Private ... that the company,s novel computational platform technology (VOLVOX) for ...
(Date:4/20/2015)... Global Stem Cells Group today announced ... gathering of aesthetic medicine experts and innovators. GSCG Advisory ... the company’s brand new training course that combines facial ... , The course is designed to address the ... including facial aging caused by volume loss. , ...
(Date:4/17/2015)... PA (PRWEB) April 17, 2015 ... a leader in regulatory data management, preparation, and submission ... today the availability of a new Lot Distribution Report ... are required to remain compliant with the FDA’s new ... by the FDA to monitor the volume and timing ...
(Date:4/17/2015)... , April 17, 2015  US-Australian drug discovery company, ... Memorandum of Understanding with the Feinstein Institute for ... York to collaborate with the objective ... The collaboration brings together the drug discovery ... expertise of the Feinstein Institute in neurosciences and ...
Breaking Biology Technology:Invictus Oncology Announces Two Posters to be Presented Describing its Platform Technology on Supramolecular Therapeutics at the American Association for Cancer Research Annual Meeting, 2015 2Global Stem Cells Group to Host Featured Speaker at The Aesthetic Meeting 2015 in Montreal 2Global Stem Cells Group to Host Featured Speaker at The Aesthetic Meeting 2015 in Montreal 3Reed Tech Announces FDA Lot Distribution Report (LDR) Service for Manufacturers of Biologic Products 2Reed Tech Announces FDA Lot Distribution Report (LDR) Service for Manufacturers of Biologic Products 3Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 2Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 3Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 4Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 5Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 6
... 3 Catalyst,Pharmaceutical Partners, Inc. (Nasdaq: CPRX ... and commercializes prescription,drugs for the treatment of drug ... J. McEnany, Chief Executive,Officer, will be presenting an ... 10th Annual Global Investment Conference on Tuesday, November ...
... - Oncolytics Biotech Inc. (TSX:,ONC, NASDAQ: ONCY) announced ... its U.K. combination REOLYSIN(R) and docetaxel clinical trial,for ... of the Royal Surrey Hospital, U.K., presented the,results ... Cancer,(iSBTC) annual meeting on November 1, 2008. The ...
... AEterna Zentaris Inc.,(NASDAQ: AEZS ; TSX: AEZ), ... oncology, today reported that it has entered the,second ... trial in endometrial,cancer with AEZS-108, a luteinizing hormone-releasing ... enter the second stage of,patient recruitment was taken ...
Cached Biology Technology:Catalyst Pharmaceutical Partners to Present at the Rodman & Renshaw 10th Annual Global Investment Conference 2Oncolytics Biotech Inc. Collaborators Present Positive Combination REOLYSIN(R) and Docetaxel Results at iSBTc Annual Meeting 2Oncolytics Biotech Inc. Collaborators Present Positive Combination REOLYSIN(R) and Docetaxel Results at iSBTc Annual Meeting 3Oncolytics Biotech Inc. Collaborators Present Positive Combination REOLYSIN(R) and Docetaxel Results at iSBTc Annual Meeting 4AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 2AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 3AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 4AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 5
(Date:3/24/2015)... , March 24, 2015   Crossmatch ... solutions, today announced that its U.are.U ® ... retailer Goorin Bros . to achieve PCI ... solution secures access to the POS terminal, protecting ... risk of data breaches. With ...
(Date:3/20/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/4stcg3/india_sensors ) ... Sensors Market Forecast and Opportunities 2020" report ... is projected to grow at a CAGR over ... industrial and healthcare sectors are the key application ... adoption of MEMS technology in sensors is growing ...
(Date:3/18/2015)... , March 18, 2015 As ... businesses, new revolutionary smart wallets and apps continue to be ... currently entrenched in the mobile payment industry in focus today ... Holding Ltd. (NYSE: BABA ), Apple Inc. (NASDAQ: ... ) and Facebook Inc. (NASDAQ: FB ) ...
Breaking Biology News(10 mins):Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 2Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 4Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 6
... become embedded in genomic DNA, which contains the complete ... for cells. It is known that ribonucleotides in DNA ... genomic instability and altered DNA metabolism, but not much ... A new study provides a mechanistic explanation of how ...
... MD -- The Biophysical Society has announced the ... to attend the Biophysical Society,s 56th Annual Meeting ... Diego, California, February 25-29, 2012. The purpose of ... interaction between American biophysicists and scientists working in ...
... can lead to climate change adaptation practices in ... "Climate-smart agriculture has the potential to increase sustainable ... climate impacts and mitigate climate change through greenhouse ... Neufeldt the lead expert on climate change at ...
Cached Biology News:Study identifies mechanisms cells use to remove bits of RNA from DNA strands 2Biophysical Society Announces winners of 2012 International Relations Committee travel awards 2Biophysical Society Announces winners of 2012 International Relations Committee travel awards 3Biophysical Society Announces winners of 2012 International Relations Committee travel awards 4Climate-smart agriculture should be livelihood-smart too 2Climate-smart agriculture should be livelihood-smart too 3
... are designed for sequencing inserts cloned into ... or T3 RNA polymerase promoters, or lambda ... at a concentration of 0.1 µg/µl in ... DNA sequencing reactions using SequiTherm™ EXCEL™ II ...
BD BioCoat Matrigel Matrix 35 mm Culture Dishes Coating : BD MatrigelTM Basement Membrane Matrix ,Surface : ECM/attachment factors ,Surface area : 9.6 cm2 ,Dim nominal : 35 mm x 10 mm ,Vo...
BD BioCoat Collagen I 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of rat tail collagen type I....
... with AutoGen AutoGenesys, BioRobotics BioPick, BioGrid, TAS ... picking systems This CLS number is a ... Cornings product number. If showing no availability ... number (D9314) or contact customer service for ...
Biology Products: